Strides Pharma gets DCGI nod under EUA to commercialize Molnupiravir


Strides Pharma Science has received Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI) to launch Molnupiravir 200mg in India.  Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS?CoV?2 and the clinical studies have shown this drug to be active against the most common Covid?19 variants.  

Under the brand name ‘Stripiravir’, Strides has developed Molnupiravir and is commercializing the product with a group integrated supply chain for Active Pharmaceutical Ingredients and solid oral dosage from its large?scale WHO Pre?Qualified (PQ) manufacturing capacities.

Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.



Source link

Leave a Reply